MAYNE PHARMA GROUP LIMITED - Announcements

4.38%

$5.02

Market Cap $407.8M

Healthcare Drug Manufacturers - Specialty & Generic

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused... Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Announcements

Filter Results

All Price Sensitive Only

MYX	US launch of HALOETTE, a generic version of NUVARING		13/01/23	211.43KB	Share
MYX	Return of Capital - MYX (updated)		12/01/23	217.87KB	Share
MYX	JP Morgan Healthcare Conference Presentation		12/01/23	976.15KB	Share
MYX	Mayne Pharma provides update on capital management timeline	PRICE SENSITIVE	12/01/23	151.54KB	Share
MYX	Notification of buy-back - MYX		03/01/23	22.18KB	Share
MYX	Notification regarding unquoted securities - MYX		03/01/23	29.41KB	Share
MYX	MYX completes TherapeuticsMD product licensing transaction	PRICE SENSITIVE	03/01/23	108.26KB	Share
MYX	Section 708A cleansing notice		30/12/22	307.44KB	Share
MYX	Notification of cessation of securities - MYX		21/12/22	21.62KB	Share
MYX	Proposed issue of securities - MYX		05/12/22	28.68KB	Share
MYX	MYX signs license agreement for women's health products	PRICE SENSITIVE	05/12/22	186.17KB	Share
MYX	Results of Meeting		30/11/22	288.17KB	Share
MYX	Chairman's Address to Shareholders		30/11/22	268.72KB	Share
MYX	AGM presentation and business and trading update	PRICE SENSITIVE	30/11/22	985.21KB	Share
MYX	Return of Capital - MYX	PRICE SENSITIVE	28/10/22	151.27KB	Share
MYX	Dividend/Distribution - MYX	PRICE SENSITIVE	28/10/22	194KB	Share
MYX	Consolidation/Split - MYX		28/10/22	25.53KB	Share
MYX	2022 AGM Notice of meeting and shareholder pack		28/10/22	1.58MB	Share
MYX	Mayne Pharma capital management update	PRICE SENSITIVE	28/10/22	156.76KB	Share
MYX	Notification of cessation of securities - MYX		26/10/22	21.63KB	Share
MYX	Annual Report to shareholders		13/10/22	3.82MB	Share
MYX	2022 Corporate Governance Statement and Appendix 4G		13/10/22	802.71KB	Share
MYX	Mayne Pharma completes sale of Metrics Contract Services	PRICE SENSITIVE	04/10/22	162.72KB	Share
MYX	Initial Director's Interest Notice		04/10/22	139.02KB	Share
MYX	Final Director's Interest Notice x2		04/10/22	685.17KB	Share
MYX	Mayne Pharma appoints new CEO	PRICE SENSITIVE	28/09/22	160.07KB	Share
MYX	Notification regarding unquoted securities - MYX		13/09/22	26.6KB	Share
MYX	Initial Director's Interest Notice		01/09/22	223.08KB	Share
MYX	Notification of cessation of securities - MYX		31/08/22	21.62KB	Share
MYX	Non-Executive Director appointment and retirement		31/08/22	146.96KB	Share
MYX	2022 Full Year Investor Presentation	PRICE SENSITIVE	26/08/22	2.74MB	Share
MYX	2022 Full Year Media Release	PRICE SENSITIVE	26/08/22	393.2KB	Share
MYX	Appendix 4E and Statutory Accounts	PRICE SENSITIVE	26/08/22	2.08MB	Share
MYX	Mayne Pharma CEO announces plan to retire	PRICE SENSITIVE	19/08/22	147.48KB	Share
MYX	Ceasing to be a substantial holder		10/08/22	200.15KB	Share
MYX	Mayne Pharma announces sale of Metrics Contract Services	PRICE SENSITIVE	10/08/22	189.91KB	Share
MYX	FDA approval of HALOETTE, a generic version of NUVARING		08/08/22	214.84KB	Share
MYX	Change of Director's Interest Notice		02/08/22	258.05KB	Share
MYX	Notification of cessation of securities - MYX		02/08/22	21.69KB	Share
MYX	NEXTSTELLIS nominated for 2022 Prix Galien USA Award		02/08/22	182.5KB	Share
MYX	Update - Notification of buy-back - MYX		02/08/22	24.12KB	Share
MYX	MYX and GoodRx announce NEXTSTELLIS DTC campaign		29/07/22	247.79KB	Share
MYX	NEXTSTELLIS oral contraceptive now available in Australia		26/07/22	206.72KB	Share
MYX	Mayne Pharma appoints new CFO		22/07/22	146.62KB	Share
MYX	Notification of buy-back - MYX		01/07/22	22.13KB	Share
MYX	Change in substantial holding		24/06/22	197.12KB	Share
MYX	Notification of cessation of securities - MYX		24/06/22	21.64KB	Share
MYX	Wilsons investor conference presentation		26/05/22	958.24KB	Share
MYX	Notice under ASX Listing Rule 3.10A		10/05/22	172.08KB	Share
MYX	Mayne Pharma recipient of $4.8m Federal Government Grant	PRICE SENSITIVE	09/05/22	95.11KB	Share
MYX	Initial Director's Interest Notice		23/03/22	222.94KB	Share
MYX	Non Executive Director Appointment		22/03/22	146.8KB	Share
MYX	Final Director's Interest Notice		01/03/22	230.65KB	Share
MYX	2022 Half Year Investor Presentation	PRICE SENSITIVE	25/02/22	1.71MB	Share
MYX	2022 Half Year Media Release	PRICE SENSITIVE	25/02/22	323.7KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/22	4.6MB	Share
MYX	Ceasing to be a substantial holder		17/02/22	516.93KB	Share
MYX	Notification of cessation of securities - MYX		10/02/22	21.64KB	Share
MYX	Mayne Pharma expands US dermatology portfolio	PRICE SENSITIVE	10/02/22	94.58KB	Share
MYX	Becoming a substantial holder		02/02/22	296.91KB	Share
MYX	Ceasing to be a substantial holder		01/02/22	498.72KB	Share
MYX	Initial Director's Interest Notice		01/02/22	227.03KB	Share
MYX	Non-Executive Director appointment and retirement		17/01/22	156.04KB	Share
MYX	Mayne Pharma adds a generic PROTOPIC to US portfolio		12/01/22	268.78KB	Share
MYX	Change of Director's Interest Notice		07/12/21	261.39KB	Share
MYX	Notification regarding unquoted securities - MYX		03/12/21	27.2KB	Share
MYX	Notification of cessation of securities - MYX		30/11/21	21.62KB	Share
MYX	TGA approval of novel oral contraceptive NEXTSTELLIS		29/11/21	216.15KB	Share
MYX	Results of Meeting		23/11/21	193.47KB	Share
MYX	2021 Mayne Pharma AGM Speeches	PRICE SENSITIVE	23/11/21	948.24KB	Share
MYX	2021 AGM Notice of Meeting and Shareholder Pack		22/10/21	5.54MB	Share
MYX	2021 Corporate Governance Statement and Appendix 4G		19/10/21	941.79KB	Share
MYX	Annual Report to shareholders		19/10/21	4.21MB	Share
MYX	MAYNE PHARMA provides FDA update on generic NUVARING		07/10/21	142.82KB	Share
MYX	Initial Director's Interest Notice		05/10/21	141.52KB	Share
MYX	Final Director's Interest Notice (x2)		04/10/21	397.57KB	Share
MYX	Mayne Pharma appoints new Director		04/10/21	146.11KB	Share
MYX	Mayne Pharma adds generic ABSORICA to US portfolio		29/09/21	153.5KB	Share
MYX	Notification regarding unquoted securities - MYX		27/09/21	27.21KB	Share
MYX	Change of Director's Interest Notice		02/09/21	196.5KB	Share
MYX	2021 Full Year Investor Presentation	PRICE SENSITIVE	27/08/21	1.13MB	Share
MYX	2021 Full Year Media Release	PRICE SENSITIVE	27/08/21	395.94KB	Share
MYX	Appendix 4E and Statutory Accounts	PRICE SENSITIVE	27/08/21	1.97MB	Share
MYX	Mayne Pharma board renewal and new Chairman		26/08/21	150.85KB	Share
MYX	Class action proceeding	PRICE SENSITIVE	03/08/21	114.64KB	Share
MYX	Notification of cessation of securities - MYX		03/08/21	21.71KB	Share
MYX	Lapse of performance rights		02/08/21	180.79KB	Share
MYX	Change of Director's Interest Notice		02/08/21	201.57KB	Share
MYX	Mayne Pharma expands Australian dermatology portfolio		21/06/21	160.4KB	Share
MYX	NEXTSTELLIS oral contraceptive now available in the US		21/06/21	134.12KB	Share
MYX	NEXTSTELLIS FDA exclusivity & phase III data published		27/05/21	223.51KB	Share
MYX	Becoming a substantial holder		14/05/21	1.21MB	Share
MYX	Appendix 2A and Notice under ASX Listing Rule 3.10A		13/05/21	955.64KB	Share
MYX	Change in substantial holding		20/04/21	284.08KB	Share
MYX	FDA approval of novel oral contraceptive NEXTSTELLIS	PRICE SENSITIVE	16/04/21	123.85KB	Share
MYX	Appendix 3G		19/03/21	402.42KB	Share
MYX	New data on NEXTSTELLIS presented at ISSWSH conference		08/03/21	154.87KB	Share
MYX	Change in substantial holding		05/03/21	991.16KB	Share
MYX	2021 Half Year Investor Presentation	PRICE SENSITIVE	24/02/21	2.76MB	Share
MYX	2021 Half Year Media Release	PRICE SENSITIVE	24/02/21	314.02KB	Share

MYX US launch of HALOETTE, a generic version of NUVARING
13/01/23		211.43KB	Share
MYX Return of Capital - MYX (updated)
12/01/23		217.87KB	Share
MYX JP Morgan Healthcare Conference Presentation
12/01/23		976.15KB	Share
MYX Mayne Pharma provides update on capital management timeline
12/01/23	PRICE SENSITIVE	151.54KB	Share
MYX Notification of buy-back - MYX
03/01/23		22.18KB	Share
MYX Notification regarding unquoted securities - MYX
03/01/23		29.41KB	Share
MYX MYX completes TherapeuticsMD product licensing transaction
03/01/23	PRICE SENSITIVE	108.26KB	Share
MYX Section 708A cleansing notice
30/12/22		307.44KB	Share
MYX Notification of cessation of securities - MYX
21/12/22		21.62KB	Share
MYX Proposed issue of securities - MYX
05/12/22		28.68KB	Share
MYX MYX signs license agreement for women's health products
05/12/22	PRICE SENSITIVE	186.17KB	Share
MYX Results of Meeting
30/11/22		288.17KB	Share
MYX Chairman's Address to Shareholders
30/11/22		268.72KB	Share
MYX AGM presentation and business and trading update
30/11/22	PRICE SENSITIVE	985.21KB	Share
MYX Return of Capital - MYX
28/10/22	PRICE SENSITIVE	151.27KB	Share
MYX Dividend/Distribution - MYX
28/10/22	PRICE SENSITIVE	194KB	Share
MYX Consolidation/Split - MYX
28/10/22		25.53KB	Share
MYX 2022 AGM Notice of meeting and shareholder pack
28/10/22		1.58MB	Share
MYX Mayne Pharma capital management update
28/10/22	PRICE SENSITIVE	156.76KB	Share
MYX Notification of cessation of securities - MYX
26/10/22		21.63KB	Share
MYX Annual Report to shareholders
13/10/22		3.82MB	Share
MYX 2022 Corporate Governance Statement and Appendix 4G
13/10/22		802.71KB	Share
MYX Mayne Pharma completes sale of Metrics Contract Services
04/10/22	PRICE SENSITIVE	162.72KB	Share
MYX Initial Director's Interest Notice
04/10/22		139.02KB	Share
MYX Final Director's Interest Notice x2
04/10/22		685.17KB	Share
MYX Mayne Pharma appoints new CEO
28/09/22	PRICE SENSITIVE	160.07KB	Share
MYX Notification regarding unquoted securities - MYX
13/09/22		26.6KB	Share
MYX Initial Director's Interest Notice
01/09/22		223.08KB	Share
MYX Notification of cessation of securities - MYX
31/08/22		21.62KB	Share
MYX Non-Executive Director appointment and retirement
31/08/22		146.96KB	Share
MYX 2022 Full Year Investor Presentation
26/08/22	PRICE SENSITIVE	2.74MB	Share
MYX 2022 Full Year Media Release
26/08/22	PRICE SENSITIVE	393.2KB	Share
MYX Appendix 4E and Statutory Accounts
26/08/22	PRICE SENSITIVE	2.08MB	Share
MYX Mayne Pharma CEO announces plan to retire
19/08/22	PRICE SENSITIVE	147.48KB	Share
MYX Ceasing to be a substantial holder
10/08/22		200.15KB	Share
MYX Mayne Pharma announces sale of Metrics Contract Services
10/08/22	PRICE SENSITIVE	189.91KB	Share
MYX FDA approval of HALOETTE, a generic version of NUVARING
08/08/22		214.84KB	Share
MYX Change of Director's Interest Notice
02/08/22		258.05KB	Share
MYX Notification of cessation of securities - MYX
02/08/22		21.69KB	Share
MYX NEXTSTELLIS nominated for 2022 Prix Galien USA Award
02/08/22		182.5KB	Share
MYX Update - Notification of buy-back - MYX
02/08/22		24.12KB	Share
MYX MYX and GoodRx announce NEXTSTELLIS DTC campaign
29/07/22		247.79KB	Share
MYX NEXTSTELLIS oral contraceptive now available in Australia
26/07/22		206.72KB	Share
MYX Mayne Pharma appoints new CFO
22/07/22		146.62KB	Share
MYX Notification of buy-back - MYX
01/07/22		22.13KB	Share
MYX Change in substantial holding
24/06/22		197.12KB	Share
MYX Notification of cessation of securities - MYX
24/06/22		21.64KB	Share
MYX Wilsons investor conference presentation
26/05/22		958.24KB	Share
MYX Notice under ASX Listing Rule 3.10A
10/05/22		172.08KB	Share
MYX Mayne Pharma recipient of $4.8m Federal Government Grant
09/05/22	PRICE SENSITIVE	95.11KB	Share
MYX Initial Director's Interest Notice
23/03/22		222.94KB	Share
MYX Non Executive Director Appointment
22/03/22		146.8KB	Share
MYX Final Director's Interest Notice
01/03/22		230.65KB	Share
MYX 2022 Half Year Investor Presentation
25/02/22	PRICE SENSITIVE	1.71MB	Share
MYX 2022 Half Year Media Release
25/02/22	PRICE SENSITIVE	323.7KB	Share
MYX Half Yearly Report and Accounts
25/02/22	PRICE SENSITIVE	4.6MB	Share
MYX Ceasing to be a substantial holder
17/02/22		516.93KB	Share
MYX Notification of cessation of securities - MYX
10/02/22		21.64KB	Share
MYX Mayne Pharma expands US dermatology portfolio
10/02/22	PRICE SENSITIVE	94.58KB	Share
MYX Becoming a substantial holder
02/02/22		296.91KB	Share
MYX Ceasing to be a substantial holder
01/02/22		498.72KB	Share
MYX Initial Director's Interest Notice
01/02/22		227.03KB	Share
MYX Non-Executive Director appointment and retirement
17/01/22		156.04KB	Share
MYX Mayne Pharma adds a generic PROTOPIC to US portfolio
12/01/22		268.78KB	Share
MYX Change of Director's Interest Notice
07/12/21		261.39KB	Share
MYX Notification regarding unquoted securities - MYX
03/12/21		27.2KB	Share
MYX Notification of cessation of securities - MYX
30/11/21		21.62KB	Share
MYX TGA approval of novel oral contraceptive NEXTSTELLIS
29/11/21		216.15KB	Share
MYX Results of Meeting
23/11/21		193.47KB	Share
MYX 2021 Mayne Pharma AGM Speeches
23/11/21	PRICE SENSITIVE	948.24KB	Share
MYX 2021 AGM Notice of Meeting and Shareholder Pack
22/10/21		5.54MB	Share
MYX 2021 Corporate Governance Statement and Appendix 4G
19/10/21		941.79KB	Share
MYX Annual Report to shareholders
19/10/21		4.21MB	Share
MYX MAYNE PHARMA provides FDA update on generic NUVARING
07/10/21		142.82KB	Share
MYX Initial Director's Interest Notice
05/10/21		141.52KB	Share
MYX Final Director's Interest Notice (x2)
04/10/21		397.57KB	Share
MYX Mayne Pharma appoints new Director
04/10/21		146.11KB	Share
MYX Mayne Pharma adds generic ABSORICA to US portfolio
29/09/21		153.5KB	Share
MYX Notification regarding unquoted securities - MYX
27/09/21		27.21KB	Share
MYX Change of Director's Interest Notice
02/09/21		196.5KB	Share
MYX 2021 Full Year Investor Presentation
27/08/21	PRICE SENSITIVE	1.13MB	Share
MYX 2021 Full Year Media Release
27/08/21	PRICE SENSITIVE	395.94KB	Share
MYX Appendix 4E and Statutory Accounts
27/08/21	PRICE SENSITIVE	1.97MB	Share
MYX Mayne Pharma board renewal and new Chairman
26/08/21		150.85KB	Share
MYX Class action proceeding
03/08/21	PRICE SENSITIVE	114.64KB	Share
MYX Notification of cessation of securities - MYX
03/08/21		21.71KB	Share
MYX Lapse of performance rights
02/08/21		180.79KB	Share
MYX Change of Director's Interest Notice
02/08/21		201.57KB	Share
MYX Mayne Pharma expands Australian dermatology portfolio
21/06/21		160.4KB	Share
MYX NEXTSTELLIS oral contraceptive now available in the US
21/06/21		134.12KB	Share
MYX NEXTSTELLIS FDA exclusivity & phase III data published
27/05/21		223.51KB	Share
MYX Becoming a substantial holder
14/05/21		1.21MB	Share
MYX Appendix 2A and Notice under ASX Listing Rule 3.10A
13/05/21		955.64KB	Share
MYX Change in substantial holding
20/04/21		284.08KB	Share
MYX FDA approval of novel oral contraceptive NEXTSTELLIS
16/04/21	PRICE SENSITIVE	123.85KB	Share
MYX Appendix 3G
19/03/21		402.42KB	Share
MYX New data on NEXTSTELLIS presented at ISSWSH conference
08/03/21		154.87KB	Share
MYX Change in substantial holding
05/03/21		991.16KB	Share
MYX 2021 Half Year Investor Presentation
24/02/21	PRICE SENSITIVE	2.76MB	Share
MYX 2021 Half Year Media Release
24/02/21	PRICE SENSITIVE	314.02KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $5.02		Change -0.230(4.38%)		Mkt cap ! $407.8M

Open	High	Low	Value	Volume
$5.17	$5.18	$4.95	$1.129M	224.1K

Buyers (Bids)

No.	Vol.	Price($)
1	1227	$5.02

Sellers (Offers)

Price($)	Vol.	No.
$5.17	1580	1

View Market Depth

No.	Vol.	Price($)
1	1227	5.020
1	7069	5.000
1	2000	4.950
1	10000	4.920
2	1849	4.910

Price($)	Vol.	No.
5.170	1580	1
5.250	17000	3
5.280	2000	2
5.290	1000	1
5.300	49100	6

Last trade - 16.10pm 29/07/2025 (20 minute delay)

MYX (ASX) Chart

MAYNE PHARMA GROUP LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories